Roth Capital Issues Positive Outlook for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at Roth Capital boosted their Q1 2025 earnings per share (EPS) estimates for Zevra Therapeutics in a report issued on Sunday, February 9th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings per share of ($0.27) for the quarter, up from their previous estimate of ($0.30). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at $0.01 EPS, Q4 2025 earnings at $0.09 EPS, FY2025 earnings at ($0.17) EPS, FY2026 earnings at $0.82 EPS, FY2027 earnings at $1.53 EPS and FY2028 earnings at $1.97 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. During the same quarter last year, the company posted ($0.40) EPS.

A number of other research analysts have also recently issued reports on the company. Canaccord Genuity Group lowered their price objective on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Cantor Fitzgerald raised Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 29th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $21.57.

Zevra Therapeutics Price Performance

ZVRA stock opened at $7.54 on Wednesday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The firm has a 50 day moving average price of $8.33 and a 200-day moving average price of $8.02. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76. The firm has a market capitalization of $402.46 million, a price-to-earnings ratio of -3.83 and a beta of 2.00.

Hedge Funds Weigh In On Zevra Therapeutics

Several institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company lifted its position in Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after purchasing an additional 2,452 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in Zevra Therapeutics during the 2nd quarter worth approximately $474,000. SG Americas Securities LLC purchased a new position in Zevra Therapeutics during the third quarter valued at approximately $105,000. IFG Advisors LLC increased its stake in shares of Zevra Therapeutics by 41.2% in the third quarter. IFG Advisors LLC now owns 26,400 shares of the company’s stock worth $183,000 after purchasing an additional 7,700 shares in the last quarter. Finally, International Assets Investment Management LLC raised its position in shares of Zevra Therapeutics by 594.0% during the 3rd quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after purchasing an additional 5,940 shares during the period. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.